Data published in ACS Central Science on July 17, 2025, has unveiled next-generation technology capable of identifying HMGB1 in period blood, which may be used as a biomarker for endometriosis.1
Breakthrough endometriosis test detects biomarker in menstrual blood | Contemporary OB/GYN
A new device identifies HMGB1 in period blood with 500% greater sensitivity, offering a faster alternative for diagnosing endometriosis.
www.contemporaryobgyn.net
November 12, 2025 at 6:30 PM
Data published in ACS Central Science on July 17, 2025, has unveiled next-generation technology capable of identifying HMGB1 in period blood, which may be used as a biomarker for endometriosis.1
Need more spatial context beyond single biomarker IHC?
Orion LE is your entry point into multiplex spatial biology by delivering high-plex immunofluorescence with a standard pathology workflow.
Learn more: rarecyte.com/orion-instru...
#Pathology #Immunofluorescence #SpatialBiology
Orion LE is your entry point into multiplex spatial biology by delivering high-plex immunofluorescence with a standard pathology workflow.
Learn more: rarecyte.com/orion-instru...
#Pathology #Immunofluorescence #SpatialBiology
November 12, 2025 at 5:53 PM
Need more spatial context beyond single biomarker IHC?
Orion LE is your entry point into multiplex spatial biology by delivering high-plex immunofluorescence with a standard pathology workflow.
Learn more: rarecyte.com/orion-instru...
#Pathology #Immunofluorescence #SpatialBiology
Orion LE is your entry point into multiplex spatial biology by delivering high-plex immunofluorescence with a standard pathology workflow.
Learn more: rarecyte.com/orion-instru...
#Pathology #Immunofluorescence #SpatialBiology
AMP® PDRD is accepting applications from clinical investigators with study cohorts in #Parkinsons or related disorders.
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
November 12, 2025 at 5:38 PM
AMP® PDRD is accepting applications from clinical investigators with study cohorts in #Parkinsons or related disorders.
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
Selected projects will receive fully funded biomarker analyses, at no cost to investigators 🧪
🧠 Apply by November 21, 2025
🔗 See the RFA: bit.ly/49yx7oW
New research reveals that specific proteomic markers can predict mortality in people with coronary artery disease. 🔬❤️ This opens the door to biomarker-guided risk stratification beyond traditional clinical measures.
https://ow.ly/yy4O50XqF2o
#PreventiveCardiology #CardioResearch
https://ow.ly/yy4O50XqF2o
#PreventiveCardiology #CardioResearch
November 12, 2025 at 5:33 PM
New research reveals that specific proteomic markers can predict mortality in people with coronary artery disease. 🔬❤️ This opens the door to biomarker-guided risk stratification beyond traditional clinical measures.
https://ow.ly/yy4O50XqF2o
#PreventiveCardiology #CardioResearch
https://ow.ly/yy4O50XqF2o
#PreventiveCardiology #CardioResearch
It's Day 3 of ASTMH 2025 and the Johns Hopkins Malaria Research Institute is bringing you highlights. Our friend Dr. Himanshu Gupta from GLA University tells us about his exciting research to see if mRNA can be used as a biomarker for severe #malaria. Spoiler alert: it can!
November 12, 2025 at 5:16 PM
It's Day 3 of ASTMH 2025 and the Johns Hopkins Malaria Research Institute is bringing you highlights. Our friend Dr. Himanshu Gupta from GLA University tells us about his exciting research to see if mRNA can be used as a biomarker for severe #malaria. Spoiler alert: it can!
(IJMS) Generative Mass Spectrometry via Physics-Informed Machine Learning: A Framework for Biomarker Discovery in Neurodegenerative Diseases: Publication date: Available online 11 November 2025
Source: International Journal of Mass Spectrometry
Author(s): Hadja Fatima Tbahriti,… #ijms #MassSpecRSS
Source: International Journal of Mass Spectrometry
Author(s): Hadja Fatima Tbahriti,… #ijms #MassSpecRSS
Generative Mass Spectrometry via Physics-Informed Machine Learning: A Framework for Biomarker Discovery in Neurodegenerative Diseases
Publication date: Available online 11 November 2025
Source: International Journal of Mass Spectrometry
Author(s): Hadja Fatima Tbahriti, Ali Boukadoum, Esraa Mohamed Ahmed Mohamed Eljamil
dlvr.it
November 12, 2025 at 5:07 PM
(IJMS) Generative Mass Spectrometry via Physics-Informed Machine Learning: A Framework for Biomarker Discovery in Neurodegenerative Diseases: Publication date: Available online 11 November 2025
Source: International Journal of Mass Spectrometry
Author(s): Hadja Fatima Tbahriti,… #ijms #MassSpecRSS
Source: International Journal of Mass Spectrometry
Author(s): Hadja Fatima Tbahriti,… #ijms #MassSpecRSS
Logistic regression analysis showed that TNFAIP3 was an independent predictor of CHD, with high accuracy in identifying those at risk. These findings suggest that TNFAIP3 could be a valuable clinical biomarker for early detection and management of heart disease.
November 12, 2025 at 4:40 PM
Logistic regression analysis showed that TNFAIP3 was an independent predictor of CHD, with high accuracy in identifying those at risk. These findings suggest that TNFAIP3 could be a valuable clinical biomarker for early detection and management of heart disease.
Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study | BMC Gastroenterology
https://www.newsbeep.com/il/129360/
The present study set out with the objective of investigating the …
https://www.newsbeep.com/il/129360/
The present study set out with the objective of investigating the …
Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study | BMC Gastroenterology - Israel News Beep
The present study set out with the objective of investigating the relationship between serum complement proteins (C1q, C3, C4, and total complement) and MASLD
www.newsbeep.com
November 12, 2025 at 3:45 PM
Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study | BMC Gastroenterology
https://www.newsbeep.com/il/129360/
The present study set out with the objective of investigating the …
https://www.newsbeep.com/il/129360/
The present study set out with the objective of investigating the …
Interactive effects of blood–brain barrier breakdown and Alzheimer's disease biomarker status on cognitive decline in older adults without dementia alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Interactive effects of blood–brain barrier breakdown and Alzheimer's disease biomarker status on cognitive decline in older adults without dementia
INTRODUCTION Some research suggests that blood–brain barrier (BBB) integrity is altered in Alzheimer's disease (AD). Few studies have examined markers of BBB integrity and their interactions with AD...
alz-journals.onlinelibrary.wiley.com
November 12, 2025 at 3:10 PM
Interactive effects of blood–brain barrier breakdown and Alzheimer's disease biomarker status on cognitive decline in older adults without dementia alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Is next-generation sequencing for rare disease diagnosis worth the cost? A user-based approach to valuation
Lewis, C., Skicon, H., Jones, R.: Living without a diagnosis: A parent's experience. genet. test. mole. Biomarker 14(6), 807–815 (2010) article pubmed Google Scholar Michaels-Igbokwe, C.,…
Lewis, C., Skicon, H., Jones, R.: Living without a diagnosis: A parent's experience. genet. test. mole. Biomarker 14(6), 807–815 (2010) article pubmed Google Scholar Michaels-Igbokwe, C.,…
Is next-generation sequencing for rare disease diagnosis worth the cost? A user-based approach to valuation
Lewis, C., Skicon, H., Jones, R.: Living without a diagnosis: A parent's experience. genet. test. mole. Biomarker 14(6), 807–815 (2010) article pubmed Google Scholar Michaels-Igbokwe, C., McInnes, B., MacDonald, KV, et al.: (Non-)standardized testing: a diagnostic odyssey in children with rare genetic disorders in Alberta, Canada. genetics in medicine 23(2), 272–9 (2021) article pubmed Google Scholar Oei, K., Hayeems, RZ, Ungar, WJ, Cohn, RD, Cohen, E.: Genetic testing in children in complex treatment programs.
healthnova.io
November 12, 2025 at 2:53 PM
Is next-generation sequencing for rare disease diagnosis worth the cost? A user-based approach to valuation
Lewis, C., Skicon, H., Jones, R.: Living without a diagnosis: A parent's experience. genet. test. mole. Biomarker 14(6), 807–815 (2010) article pubmed Google Scholar Michaels-Igbokwe, C.,…
Lewis, C., Skicon, H., Jones, R.: Living without a diagnosis: A parent's experience. genet. test. mole. Biomarker 14(6), 807–815 (2010) article pubmed Google Scholar Michaels-Igbokwe, C.,…
Shuji Ogino delivered the keynote lecture ‘Assessing long-term risk factor exposures is a critical gap in early-onset cancer research: how can we overcome it using tumour biomarker analyses?’
November 12, 2025 at 2:15 PM
Shuji Ogino delivered the keynote lecture ‘Assessing long-term risk factor exposures is a critical gap in early-onset cancer research: how can we overcome it using tumour biomarker analyses?’
Immune cell activity fluctuates throughout the day, but overall immune age, measured by the IMMAX biomarker, remains stable regardless of the time of blood sampling. doi.org/g995zm
The internal clock of immune cells: Is the immune system younger in the morning?
As the immune system ages, it reacts more slowly to pathogens, vaccines become less effective, and the risk of cancer increases.
medicalxpress.com
November 12, 2025 at 2:00 PM
Immune cell activity fluctuates throughout the day, but overall immune age, measured by the IMMAX biomarker, remains stable regardless of the time of blood sampling. doi.org/g995zm
Join us next week for our Evosep webinar with Margret Thorsteinsdottir & Finnur Freyr Eiriksson (Univ. of Iceland)! Discover how the Evosep Eno + Waters Xevo TQ Absolute enable precise, high-throughput #plasma biomarker quantification. Register: www.evosep.com/webinars/web...
November 12, 2025 at 12:47 PM
Join us next week for our Evosep webinar with Margret Thorsteinsdottir & Finnur Freyr Eiriksson (Univ. of Iceland)! Discover how the Evosep Eno + Waters Xevo TQ Absolute enable precise, high-throughput #plasma biomarker quantification. Register: www.evosep.com/webinars/web...
📃Scientific paper: An Oculomotor Digital Parkinson Biomarker From a Deep Riemannian Representation
Ref.: HAL CCSD, 2022
➡️ Continued on ES/IODE
Ref.: HAL CCSD, 2022
➡️ Continued on ES/IODE
November 12, 2025 at 12:00 PM
📃Scientific paper: An Oculomotor Digital Parkinson Biomarker From a Deep Riemannian Representation
Ref.: HAL CCSD, 2022
➡️ Continued on ES/IODE
Ref.: HAL CCSD, 2022
➡️ Continued on ES/IODE
The VasCog-2-WSO criteria provide updated international guidelines for diagnosing vascular cognitive impairment and #dementia, incorporating recent biomarker advancements. ja.ma/3Lzrj4U
November 12, 2025 at 12:00 PM
The VasCog-2-WSO criteria provide updated international guidelines for diagnosing vascular cognitive impairment and #dementia, incorporating recent biomarker advancements. ja.ma/3Lzrj4U
Profiling fear-extinction learning induced small ncRNAs landscape and identifying miR-29b-3p as a promising biomarker for PTSD
doi.org/10.1186/s129...
doi.org/10.1186/s129...
Profiling fear-extinction learning induced small ncRNAs landscape and identifying miR-29b-3p as a promising biomarker for PTSD - Journal of Translational Medicine
The pivotal role of small non-coding RNAs (ncRNAs) in gene expression highlights their potential as therapeutic targets and biomarkers in neuropsychiatric disorders. However, their transcriptional dyn...
doi.org
November 12, 2025 at 10:31 AM
Profiling fear-extinction learning induced small ncRNAs landscape and identifying miR-29b-3p as a promising biomarker for PTSD
doi.org/10.1186/s129...
doi.org/10.1186/s129...
Prof. Jens Kuhle zählt zu den «Highly Cited Researchers 2025»
Der DKF-Forschungsgruppenleiter wird weltweit besonders häufig zitiert. Seine Forschung zur Multiplen Sklerose stärkt die Entwicklung neuer Biomarker und Therapien – ein bedeutender Beitrag zur klinischen Forschung in Basel.
@unibas.ch
Der DKF-Forschungsgruppenleiter wird weltweit besonders häufig zitiert. Seine Forschung zur Multiplen Sklerose stärkt die Entwicklung neuer Biomarker und Therapien – ein bedeutender Beitrag zur klinischen Forschung in Basel.
@unibas.ch
Clarivate Highly Cited Researchers 2025
The Highly Cited Researchers 2025 list identifies and celebrates individuals who have demonstrated significant and broad influence in their fields of research. Through rigorous selection criteria and ...
clarivate.com
November 12, 2025 at 10:09 AM
Prof. Jens Kuhle zählt zu den «Highly Cited Researchers 2025»
Der DKF-Forschungsgruppenleiter wird weltweit besonders häufig zitiert. Seine Forschung zur Multiplen Sklerose stärkt die Entwicklung neuer Biomarker und Therapien – ein bedeutender Beitrag zur klinischen Forschung in Basel.
@unibas.ch
Der DKF-Forschungsgruppenleiter wird weltweit besonders häufig zitiert. Seine Forschung zur Multiplen Sklerose stärkt die Entwicklung neuer Biomarker und Therapien – ein bedeutender Beitrag zur klinischen Forschung in Basel.
@unibas.ch
Congrats to Sara Wernig-Zorc for completing the Clinical Trials program at Harvard Medical School, with distinction! 🎓👏 Her capstone on biomarker-driven immunotherapy in neuroblastoma was recognized for excellence. #ClinicalResearch #HarvardMed #Neuroblastoma ©Liesl Clark
November 12, 2025 at 9:48 AM
Congrats to Sara Wernig-Zorc for completing the Clinical Trials program at Harvard Medical School, with distinction! 🎓👏 Her capstone on biomarker-driven immunotherapy in neuroblastoma was recognized for excellence. #ClinicalResearch #HarvardMed #Neuroblastoma ©Liesl Clark
This study evaluated the differences in Fat Attenuation Index (FAI), a sensitive biomarker for coronary inflammation, using three reconstruction algorithms: DLIR-H, ASIR-V, and FBP.
November 12, 2025 at 6:56 AM
This study evaluated the differences in Fat Attenuation Index (FAI), a sensitive biomarker for coronary inflammation, using three reconstruction algorithms: DLIR-H, ASIR-V, and FBP.
CND Life Sciences’ Syn-One Biomarker Services Used in Phase 2 Parkinson’s Trial
CND Life Sciences announced that its Syn-One Biomarker Services were utilized in a Phase 2 clinical trial by ABLi Therapeutics for risvodetinib, an investigational Parkinson's disease treatment. The exploratory…
CND Life Sciences announced that its Syn-One Biomarker Services were utilized in a Phase 2 clinical trial by ABLi Therapeutics for risvodetinib, an investigational Parkinson's disease treatment. The exploratory…
CND Life Sciences’ Syn-One Biomarker Services Used in Phase 2 Parkinson’s Trial
CND Life Sciences announced that its Syn-One Biomarker Services were utilized in a Phase 2 clinical trial by ABLi Therapeutics for risvodetinib, an investigational Parkinson's disease treatment. The exploratory analysis demonstrated a reduction in phosphorylated alpha-synuclein deposition in cutaneous nerves after 12 weeks of treatment. Results were presented at the 2025 Movement Disorders Society Congress. The Syn-One Services integrate the Syn-One Research Test with the AI-powered digital pathology platform NerValence to detect, visualize, and quantify abnormal alpha-synuclein in skin nerves.
labnews.io
November 12, 2025 at 4:19 AM
CND Life Sciences’ Syn-One Biomarker Services Used in Phase 2 Parkinson’s Trial
CND Life Sciences announced that its Syn-One Biomarker Services were utilized in a Phase 2 clinical trial by ABLi Therapeutics for risvodetinib, an investigational Parkinson's disease treatment. The exploratory…
CND Life Sciences announced that its Syn-One Biomarker Services were utilized in a Phase 2 clinical trial by ABLi Therapeutics for risvodetinib, an investigational Parkinson's disease treatment. The exploratory…
Congratulations to A/Prof Yuen Yee Cheng on receiving a 2026 Inspirational Research Grant.
We're excited to follow your research in "Biomarker Discovery for Predicting Immunotherapy Response in Mesothelioma Patients".
Designed to drive meaningful impact, the Inspirational
We're excited to follow your research in "Biomarker Discovery for Predicting Immunotherapy Response in Mesothelioma Patients".
Designed to drive meaningful impact, the Inspirational
November 12, 2025 at 3:45 AM
Congratulations to A/Prof Yuen Yee Cheng on receiving a 2026 Inspirational Research Grant.
We're excited to follow your research in "Biomarker Discovery for Predicting Immunotherapy Response in Mesothelioma Patients".
Designed to drive meaningful impact, the Inspirational
We're excited to follow your research in "Biomarker Discovery for Predicting Immunotherapy Response in Mesothelioma Patients".
Designed to drive meaningful impact, the Inspirational
that certainly does not look like the studies used our darling's definition of ultraprocessed foods, on account of there not being any foods at all in the selected studies...
![Selection Criteria
Study type.
Studies with a prospective cohort design and at least 2 years follow up were included to allow the predictive value of biomarkers to be assessed. Where studies investigated disease prevention, only primary prevention studies were included. For Medline and Embase, standardised filters from BMJ Evidence [23] which return cohort studies were used. Equivalent versions were not available for Web of Science and Scopus, so topic searching and index terms respectively were used to search for cohort studies. Searches were conducted up to March 2014.
Participants.
Studies that included human participants, of either sex, with blood-borne biomarker data available for participants with a mean age of 50–75 years at baseline were included. Studies that recruited participants based on risk factors for a disease, rather than presence of the disease itself, were included as these studies were likely to focus on primary prevention.
Outcome measures.
This review was restricted to studies examining biomarkers that are blood-borne and where a relationship with mortality was reported. Studies that examined genetic factors or biomarkers diagnostic of a particular disease rather than mortality risk were not included in this review.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:zvgcibjxplwphdq3azgxv22j/bafkreicqfuxlad223qr5i6r64eoiuomcvymfp36pzwfrc2vlbgeooz3mvq@jpeg)
November 12, 2025 at 3:03 AM
that certainly does not look like the studies used our darling's definition of ultraprocessed foods, on account of there not being any foods at all in the selected studies...
The combined diagnostic performance of IgG glycosylation traits and inflammatory factors outperformed either alone, highlighting their potential as a novel biomarker for AS.
November 12, 2025 at 2:55 AM
The combined diagnostic performance of IgG glycosylation traits and inflammatory factors outperformed either alone, highlighting their potential as a novel biomarker for AS.
"For expectant parents, the wait is over. Accurate, discreet & affordable pregnancy test alternatives are changing the game. From at-home kits to biomarker innovations, we're breaking down the latest advancements in reproductive... cheap groceries: https://tinyurl.com/bstgrocery
cheap groceries
Related to Pregnancy Test
tinyurl.com
November 12, 2025 at 2:19 AM
"For expectant parents, the wait is over. Accurate, discreet & affordable pregnancy test alternatives are changing the game. From at-home kits to biomarker innovations, we're breaking down the latest advancements in reproductive... cheap groceries: https://tinyurl.com/bstgrocery
These findings highlight the potential of PTPN6 as a prognostic biomarker and therapeutic target, though further research is needed to fully elucidate its clinical applications.
November 12, 2025 at 12:34 AM
These findings highlight the potential of PTPN6 as a prognostic biomarker and therapeutic target, though further research is needed to fully elucidate its clinical applications.